Cyclophosphamide (generic), Cytoxan Newswire (Page 7)

Cyclophosphamide (generic), Cytoxan Newswire (Page 7)

Comprehensive Real-Time News Feed for Cyclophosphamide (generic), Cytoxan. (Page 7)

Results 121 - 140 of 901 in Cyclophosphamide (generic), Cytoxan

  1. GlaxoSmithKline Announces Positive Results In Fourth Consecutive...Read the original story

    Nov 13, 2016 | BioSpace

    GSK today announced positive efficacy and safety data from a pivotal study of patients with systemic lupus erythematosus in ). In the study, being presented at the 2016 American College of Rheumatology/Association for Rheumatology Health Professionals Annual Meeting , BenlystaA achieved the primary and all four pre-specified secondary endpoints with statistical significance.

    Comment?

  2. Aduro Biotech Highlights Positive Clinical Results from Second Cohort ...Read the original story

    Nov 12, 2016 | Customer Interaction Solutions

    Aduro Biotech, Inc. today announced highlights from a poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer being held in National Harbor, Maryland on the preliminary safety and efficacy of its novel immunotherapy, CRS-207, being evaluated in unresectable malignant pleural mesothelioma. These data were from the second cohort of patients in an ongoing Phase 1b clinical trial of CRS-207 in combination with standard of care chemotherapy and immune-modulating doses of cyclophosphamide as a first-line treatment.

    Comment?

  3. European advisory committee backs expanded use of Novartis' cancer med ArzerraRead the original story w/Photo

    Nov 11, 2016 | Seeking Alpha

    The European Medicines Agency's Committee for Medicinal Products for Human Use adopts a positive opinion recommending the use of Novartis' Arzerra , in combination with the chemo agents fludarabine and cyclophosphamide, for the treatment of adult patients with relapsed chronic lymphocytic leukemia .

    Comment?

  4. Adaptimmune Therapeutics' (ADAP) CEO James Noble on Q3 2016 Results - Earnings Call TranscriptRead the original story w/Photo

    Nov 10, 2016 | Seeking Alpha

    Good day and welcome to the Quarter Three 2016 Adaptimmune Earnings Conference Call and Business Update. Today's conference is being recorded.

    Comment?

  5. BRIEF-Genmab: CHMP issues positive opinion recommending Arzerra with...Read the original story w/Photo

    Nov 10, 2016 | Reuters

    The antitrust investigations which began about two years ago have attracted investor attention recently, with news of the likely expansion of the investigation into more generic drugs and the first * CEO says Perrigo to initiate claim arbitration against sellers of Omega which we plan to do before the end of this year LONDON, Nov 10 The state health service in England has the legal power to fund an HIV pill to prevent infection, the court of appeal ruled on Thursday, in a victory for AIDS campaigners who have been calling for its widespread use.

    Comment?

  6. UPDATE 2-Sun Pharma expects U.S. drug pricing pressures to continueRead the original story w/Photo

    Nov 10, 2016 | Reuters

    MUMBAI, Nov 10 Sun Pharmaceutical Industries Ltd does not expect pressure on generic drug prices in the United States to abate anytime soon, its managing director said on Thursday, signalling a challenging year ahead in the company's largest market. Dilip Shanghvi's comments followed publication of Sun Pharma's second-quarter results in which profit more than doubled from a year earlier, driven by higher sales in nearly all its markets.

    Comment?

  7. Musings from afar - I'm a winnerRead the original story w/Photo

    Nov 10, 2016 | GhanaWeb

    I write not because I want sympathy, far from it. I believe I long won my fight against Breast Cancer.

    Comment?

  8. CHMP Issues Positive Opinion Recommending Arzerra (ofatumumab) in...Read the original story w/Photo

    Nov 10, 2016 | GlobeNewswire

    Genmab A/S announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending the use, in the European Union, of ofatumumab in combination with fludarabine and cyclophosphamide for the treatment of adult patients with relapsed chronic lymphocytic leukemia . The variation to the Marketing Authorization for this indication was submitted to the EMA in March by Novartis under the ofatumumab collaboration between Novartis and Genmab.

    Comment?

  9. Heron Reports Financial Results For The Three And Nine Months Ended...Read the original story

    Nov 8, 2016 | BioSpace

    Heron Therapeutics, Inc. , a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today reported financial results for the three and nine months ended September 30, 2016 and highlighted recent corporate progress. "The second half of 2016 is off to an exciting start for Heron, highlighted by the FDA approval and commercial launch of SUSTOL" Heron commenced U.S. commercial sales of SUSTOLA extended-release injection in October 2016.

    Comment?

  10. Immunovaccine Announces Third Quarter 2016 Financial Results and Provides Corporate UpdateRead the original story

    Nov 8, 2016 | World News Report

    Immunovaccine Inc. , a clinical-stage vaccine and immunotherapy company, today announced financial results for the third quarter ended September 30, 2016 and provided a corporate update. "Our achievements during the third quarter of 2016 reinforced the strong progress that Immunovaccine has established across all three pillars that support the long-term success and value proposition for our DepoVaxa -based pipeline," said Frederic Ors, Immunovaccine's Chief Executive Officer .

    Comment?

  11. Settlement Reached in Chemotherapy Dosing Incident Class ActionRead the original story

    Nov 7, 2016 | World News Report

    A settlement has been reached which resolves the claims of Class Members and Family Class Members in respect of the diluted chemotherapy incident at various Ontario and New Brunswick Hospitals, between February 4, 2012 and April 2, 2013. A class action was brought on behalf of individuals who alleged that the negligence of Mezentco Solutions Inc., cob Marchese Hospital Solutions, Mezentco Inc., cob Marchese Health Care and MedBuy Corporation caused approximately 1200 cancer patients in Ontario and New Brunswick to receive lower than intended dosages of the cancer drugs cyclophosphamide and/or gemcitabine.

    Comment?

  12. Seattle Genetics Announces American Society of Hematology 2016...Read the original story

    Nov 3, 2016 | BioSpace

    Seattle Genetics, Inc. today announced that 18 abstracts including eight oral presentations have been accepted for presentation at the 58th American Society of Hematology Annual Meeting and Exposition taking place in San Diego, Calif. from December 3-6, 2016.

    Comment?

  13. Seattle Genetics Announces ASH 2016 Abstracts Highlighting Company's...Read the original story

    Nov 3, 2016 | Information Technology

    Seattle Genetics, Inc. today announced that 18 abstracts including eight oral presentations have been accepted for presentation at the 58th American Society of Hematology Annual Meeting and Exposition taking place in San Diego, Calif. from December 3-6, 2016.

    Comment?

  14. Genmab's (GNMSF) CEO Jan van de Winkel on Q3 2016 Results - Earnings Call TranscriptRead the original story w/Photo

    Nov 2, 2016 | Seeking Alpha

    Good day and welcome to the Q3 Report 2016 Conference Call. Today's conference is being recorded.

    Comment?

  15. Genmab Announces Financial Results for the First Nine Months of 2016...Read the original story

    Nov 2, 2016 | P&T Community

    Net Sales of DARZALEXA by Janssen for the first nine months of 2016 were USD 372 million, resulting in royalty income of USD 45 million Announced U.S. and European regulatory submissions for daratumumab in relapsed or refractory multiple myeloma, triggering USD 25 million in milestone payments "Throughout the third quarter we continued to see excellent progress in our DARZALEX program with Janssen. Regulatory applications to expand the label for daratumumab to include relapsed or refractory multiple myeloma were submitted in the U.S. and Europe, triggering USD 25 million in milestone payments.

    Comment?

  16. The morphology of various types of cell death in prenatal tissuesRead the original story

    Nov 1, 2016 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. The morphology of physiological cell death and of necroses caused by treatment with various embryotoxic substances and Mg deficiency were studied electron microscopically in rat and mouse embryos and fetuses.

    Comment?

  17. How I manage patients with grey zone lymphomaRead the original story

    Oct 28, 2016 | CiteULike

    Since grey zone lymphoma was originally included in the 2008 World Health Organization classification as a B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma , new biological and clinical knowledge have been learned. It is important to highlight that diagnosis of this entity is complex and involvement by haematopathologists with expertise in this disease is recommended.

    Comment?

  18. Baxter International Inc Gets More EfficientRead the original story w/Photo

    Oct 26, 2016 | Fox News

    At constant currency, revenue would have been up 4% year over year. It's certainly nothing to get too excited about, but sales were hurt by generic competition for cancer medicine cyclophosphamide and the effect of a $20 million order of Protopam in the year-ago quarter.

    Comment?

  19. Baxter International (BAX) - Research Analysts' Weekly Ratings ChangesRead the original story w/Photo

    Oct 25, 2016 | AmericanBankingNews.com

    According to Zacks, "We believe Baxter is gaining prominence with a series of strategic developments that include the recent launch of NUMETA G13E in Europe for vulnerable preterm newborns, the strategic tie-up with Satellite Healthcare and the recognition of its Sigma spectrum infusion system as a highly efficient infusion pump in drug library compliance . However, intense competition in the medical products segment and unimpressive hospital spending environment are major concerns.

    Comment?

  20. Aduro told to halt cancer vaccine trial enrollment after listeria found in patient sampleRead the original story w/Photo

    Oct 25, 2016 | In-PharmaTechnologist.com

    The US FDA has told Aduro Biotech not to enrol subjects in trials of its listeria-based immunotherapies after one study subject tested positive for the bacteria. California based Aduro announced the partial clinical hold last night .

    Comment?